Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 8/20 | 0.49 |
| ▸ | CHEK2 | O96017 | 4/20 | 0.46 |
| ▸ | PARP4 | Q9UKK3 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.45 |
| ▸ | RHEB | Q15382 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.44 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.44 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17009604 | 0.84 | KDM4E (0.46) | ALDH1A1KMT2AKDM4EHPGDMAPT | |
| SCHEMBL3218684 | 0.81 | PARP10 (0.50) | PARP10CHEK2PARP4PARP2RHEB | |
| SCHEMBL12806740 | 0.79 | MEN1 (0.43) | ALDH1A1KMT2AKDM4EHPGDMAPT | |
| SCHEMBL31105544 | 0.78 | KDM4E (0.50) | ALDH1A1KDM4EHPGDMAPTTDP1 | |
| SCHEMBL31664560 | 0.76 | KDM4E (0.59) | ALDH1A1KMT2AKDM4EHPGDMAPT | |
| SCHEMBL31060830 | 0.73 | EGFR (0.52) | ALDH1A1KDM4EHPGDMAPTSMN1; SMN2 | |
| SCHEMBL30388046 | 0.72 | EGFR (0.67) | — | |
| SCHEMBL23463916 | 0.72 | ALDH1A1 (0.68) | PARP10PARP4CA1CA2PARP1 | |
| SCHEMBL11401711 | 0.71 | PARP10 (0.67) | PARP10PARP4CA1CA2PARP1 | |
| SCHEMBL3794599 | 0.71 | FGFR2 (0.69) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11504363-B2 | Method of treating cancer and bone cancer pain | EXELIXIS, INC. (US) | 2022-11-22 | — | — | US | disclosed |
| EP-3105204-A1 | CRYSTALLINE SOLID FORMS OF N-{4-[(6,7-DIMETHOXYQUINOLIN-4-YL)OXY]PHENYL}-N'-(4-FLUOROPHENYL) CYCLOPROPANE-1, 1-DICARBOXAMIDE, PROCESSES FOR MAKING, AND METHODS OF USE | Exelixis, Inc. (US) | 2016-12-21 | — | — | EP | disclosed |
| WO-2015123639-A1 | CRYSTALLINE SOLID FORMS OF N-{4-[(6,7-DIMETHOXYQUINOLIN-4-YL)OXY]PHENYL}-N'-(4-FLUOROPHENYL) CYCLOPROPANE-1, 1-DICARBOXAMIDE, PROCESSES FOR MAKING, AND METHODS OF USE | EXELIXIS, INC. (US) | 2015-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11504363-B2 | Method of treating cancer and bone cancer pain | TPO, OGFR, CALCR | PARP10 3521/4885CHEK2 2123/4885PARP4 2910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.